In total, these data suggest that the secretion of complement components (C1q and C5a/C5aR1) by PCs contributes to the development of renal fibrosis, thus the inhibition of complement activation represents a potential therapeutic target in treatment of kidney fibrosis and chronic kidney disease. This evidence concerns the gene C5AR1 and chronic kidney disease.